Nature Medicine, Published online: 27 February 2026; doi:10.1038/s41591-026-04271-3 As presented at the 2026 ASCO Genitourinary Cancers Symposium, in the phase 2 INDIBLADE trial, induction therapy with ipilimumab and nivolumab followed by consolidating chemoradiotherapy in stage II/III muscle-invasive bladder cancer led to encouraging bladder-intact event-free survival outcomes that were associated with ctDNA clearance.
Nature Medicine, Published online: 27 February 2026;
doi:10.1038/s41591-026-04271-3
As presented at the 2026 ASCO Genitourinary Cancers Symposium, in the phase 2 INDIBLADE trial, induction therapy with ipilimumab and nivolumab followed by consolidating chemoradiotherapy in stage II/III muscle-invasive bladder cancer led to encouraging bladder-intact event-free survival outcomes that were associated with ctDNA clearance.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04271-3)